Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. TPST
TPST logo

TPST Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Tempest Therapeutics Inc (TPST) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
1.080
1 Day change
2.86%
52 Week Range
12.230
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Tempest Therapeutics Inc (TPST) is not a good buy for a beginner, long-term investor at this time. The stock shows a bearish trend with no significant positive catalysts, weak technical indicators, and no recent signals from Intellectia Proprietary Trading Signals. Additionally, there is no relevant financial data or news to support a strong investment case.

Technical Analysis

The MACD histogram is positive and expanding slightly, but the RSI indicates the stock is oversold at 16.031. Moving averages are bearish (SMA_200 > SMA_20 > SMA_5), and the stock is trading below key support levels. The overall technical trend is bearish.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
9
Buy
5

Positive Catalysts

  • NULL identified. No recent news or significant trading trends from hedge funds or insiders.

Neutral/Negative Catalysts

  • Bearish technical indicators, lack of trading activity, and no recent positive news or financial performance data.

Financial Performance

No financial data available for analysis.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst ratings or price target changes available.

Wall Street analysts forecast TPST stock price to rise
Analyst Rating
0
Wall Street analysts forecast TPST stock price to rise
Buy
Hold
Sell
0
Current: 1.050
sliders
Low
0
Averages
0
High
0
0
Current: 1.050
sliders
Low
0
Averages
0
High
0
H.C. Wainwright
Joseph Pantginis
Neutral -> Buy
upgrade
$11
AI Analysis
2026-01-22
Reason
H.C. Wainwright
Joseph Pantginis
Price Target
$11
AI Analysis
2026-01-22
upgrade
Neutral -> Buy
Reason
H.C. Wainwright analyst Joseph Pantginis upgraded Tempest Therapeutics to Buy from Neutral with an $11 price target. The company's acquisition of Factor Bioscience's CAR-T programs is a "shrewd and necessary move" to extend its "critically short cash runway into 2027," the analyst tells investors in a research note. The firm Tempest's strategic pivot also expands the company's pipeline with a "clinically de-risked" cell therapy asset TPST-2003. It cites Tempest's renewed strategic focus and market opportunity for the upgrade.

People Also Watch